Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In a randomized, active-controlled trial, patients with moderately to severely active ulcerative colitis were assigned to receive vedolizumab or adalimumab. At 52 weeks, vedolizumab was superior to adalimumab in terms of clinical remission and endoscopic improvement but not in corticosteroid-free clinical remission.
Alternative Titles
Full title
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2298144402
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2298144402
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1905725
